Annual Cash & Cash Equivalents
$1.21 B
+$246.50 M+25.65%
31 December 2023
Summary:
United Therapeutics annual cash & cash equivalents is currently $1.21 billion, with the most recent change of +$246.50 million (+25.65%) on 31 December 2023. During the last 3 years, it has risen by +$469.00 million (+63.49%). UTHR annual cash & cash equivalents is now at all-time high.UTHR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$1.55 B
+$198.20 M+14.62%
30 September 2024
Summary:
United Therapeutics quarterly cash and cash equivalents is currently $1.55 billion, with the most recent change of +$198.20 million (+14.62%) on 30 September 2024. Over the past year, it has increased by +$446.20 million (+40.28%). UTHR quarterly cash and cash equivalents is now at all-time high.UTHR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
UTHR Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +25.6% | +40.3% |
| 3 y3 years | +63.5% | +71.0% |
| 5 y5 years | +80.5% | +115.9% |
UTHR Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +63.5% | at high | +95.4% |
| 5 y | 5 years | at high | +80.5% | at high | +131.9% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
United Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.55 B(+14.6%) |
| June 2024 | - | $1.36 B(+8.3%) |
| Mar 2024 | - | $1.25 B(+3.6%) |
| Dec 2023 | $1.21 B(+25.6%) | $1.21 B(+9.0%) |
| Sept 2023 | - | $1.11 B(+3.8%) |
| June 2023 | - | $1.07 B(-8.3%) |
| Mar 2023 | - | $1.16 B(+21.0%) |
| Dec 2022 | $961.20 M(+7.4%) | $961.20 M(-0.6%) |
| Sept 2022 | - | $966.80 M(+21.6%) |
| June 2022 | - | $795.20 M(-2.2%) |
| Mar 2022 | - | $813.30 M(-9.1%) |
| Dec 2021 | $894.80 M(+21.1%) | $894.80 M(-1.5%) |
| Sept 2021 | - | $908.50 M(-3.6%) |
| June 2021 | - | $942.20 M(+13.2%) |
| Mar 2021 | - | $832.30 M(+12.7%) |
| Dec 2020 | $738.70 M(+0.0%) | $738.70 M(+10.2%) |
| Sept 2020 | - | $670.20 M(-2.2%) |
| June 2020 | - | $685.40 M(-21.7%) |
| Mar 2020 | - | $875.20 M(+18.5%) |
| Dec 2019 | $738.40 M(+10.3%) | $738.40 M(+2.6%) |
| Sept 2019 | - | $719.70 M(-18.3%) |
| June 2019 | - | $881.30 M(+11.5%) |
| Mar 2019 | - | $790.60 M(+18.1%) |
| Dec 2018 | $669.20 M(-5.1%) | $669.20 M(+2.0%) |
| Sept 2018 | - | $656.00 M(-12.1%) |
| June 2018 | - | $745.90 M(-20.0%) |
| Mar 2018 | - | $932.70 M(+32.3%) |
| Dec 2017 | $705.10 M(-31.1%) | $705.10 M(-33.9%) |
| Sept 2017 | - | $1.07 B(+6.1%) |
| June 2017 | - | $1.01 B(-10.4%) |
| Mar 2017 | - | $1.12 B(+9.7%) |
| Dec 2016 | $1.02 B(+23.0%) | $1.02 B(+7.3%) |
| Sept 2016 | - | $953.00 M(+13.8%) |
| June 2016 | - | $837.50 M(-1.1%) |
| Mar 2016 | - | $846.80 M(+1.8%) |
| Dec 2015 | $831.80 M(+109.2%) | $831.80 M(+8.7%) |
| Sept 2015 | - | $765.21 M(+200.8%) |
| June 2015 | - | $254.36 M(-40.4%) |
| Mar 2015 | - | $426.51 M(+7.2%) |
| Dec 2014 | $397.70 M(+39.9%) | $397.70 M(-20.0%) |
| Sept 2014 | - | $497.29 M(+92.0%) |
| June 2014 | - | $259.05 M(-37.4%) |
| Mar 2014 | - | $413.79 M(+45.6%) |
| Dec 2013 | $284.26 M(+84.5%) | $284.26 M(-11.8%) |
| Sept 2013 | - | $322.23 M(-6.2%) |
| June 2013 | - | $343.55 M(+31.1%) |
| Mar 2013 | - | $262.13 M(+70.2%) |
| Dec 2012 | $154.03 M(-5.3%) | $154.03 M(-41.5%) |
| Sept 2012 | - | $263.43 M(+67.8%) |
| June 2012 | - | $157.01 M(+0.2%) |
| Mar 2012 | - | $156.67 M(-3.7%) |
| Dec 2011 | $162.68 M | $162.68 M(-52.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $343.98 M(+7.1%) |
| June 2011 | - | $321.12 M(+11.1%) |
| Mar 2011 | - | $288.96 M(+14.6%) |
| Dec 2010 | $252.16 M(+151.3%) | $252.16 M(+20.0%) |
| Sept 2010 | - | $210.19 M(-26.4%) |
| June 2010 | - | $285.41 M(+50.3%) |
| Mar 2010 | - | $189.96 M(+89.3%) |
| Dec 2009 | $100.35 M(-22.5%) | $100.35 M(-25.4%) |
| Sept 2009 | - | $134.50 M(+0.7%) |
| June 2009 | - | $133.52 M(+35.1%) |
| Mar 2009 | - | $98.85 M(-23.6%) |
| Dec 2008 | $129.45 M(-7.1%) | $129.45 M(+19.9%) |
| Sept 2008 | - | $107.97 M(-13.9%) |
| June 2008 | - | $125.33 M(-29.4%) |
| Mar 2008 | - | $177.65 M(+27.5%) |
| Dec 2007 | $139.32 M(+53.0%) | $139.32 M(+89.5%) |
| Sept 2007 | - | $73.54 M(-9.7%) |
| June 2007 | - | $81.48 M(+20.1%) |
| Mar 2007 | - | $67.85 M(-25.5%) |
| Dec 2006 | $91.07 M(+31.6%) | $91.07 M(+87.8%) |
| Sept 2006 | - | $48.50 M(-32.0%) |
| June 2006 | - | $71.32 M(-18.6%) |
| Mar 2006 | - | $87.62 M(+26.7%) |
| Dec 2005 | $69.18 M(-16.2%) | $69.18 M(-2.6%) |
| Sept 2005 | - | $71.02 M(+25.6%) |
| June 2005 | - | $56.53 M(-31.7%) |
| Mar 2005 | - | $82.81 M(+0.3%) |
| Dec 2004 | $82.59 M(+20.5%) | $82.59 M(-4.4%) |
| Sept 2004 | - | $86.38 M(+16.0%) |
| June 2004 | - | $74.48 M(+8.7%) |
| Mar 2004 | - | $68.52 M(-0.1%) |
| Dec 2003 | $68.56 M(-44.1%) | $68.56 M(-20.7%) |
| Sept 2003 | - | $86.44 M(-5.1%) |
| June 2003 | - | $91.07 M(-0.2%) |
| Mar 2003 | - | $91.24 M(-25.6%) |
| Dec 2002 | $122.66 M(+403.2%) | $122.66 M(-8.3%) |
| Sept 2002 | - | $133.81 M(+760.7%) |
| June 2002 | - | $15.55 M(-25.0%) |
| Mar 2002 | - | $20.73 M(-15.0%) |
| Dec 2001 | $24.37 M(-87.9%) | $24.37 M(-71.8%) |
| Sept 2001 | - | $86.48 M(-47.0%) |
| June 2001 | - | $163.29 M(-11.0%) |
| Mar 2001 | - | $183.40 M(-8.7%) |
| Dec 2000 | $200.94 M(+998.0%) | $200.94 M(-10.4%) |
| Sept 2000 | - | $224.29 M(+136.0%) |
| June 2000 | - | $95.04 M(-7.5%) |
| Mar 2000 | - | $102.79 M(+461.7%) |
| Dec 1999 | $18.30 M(+169.1%) | $18.30 M(+215.5%) |
| Sept 1999 | - | $5.80 M(+28.9%) |
| June 1999 | - | $4.50 M(-70.8%) |
| Mar 1999 | - | $15.40 M |
| Dec 1998 | $6.80 M | - |
FAQ
- What is United Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for United Therapeutics?
- What is United Therapeutics annual cash & cash equivalents year-on-year change?
- What is United Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for United Therapeutics?
- What is United Therapeutics quarterly cash and cash equivalents year-on-year change?
What is United Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of UTHR is $1.21 B
What is the all time high annual cash & cash equivalents for United Therapeutics?
United Therapeutics all-time high annual cash & cash equivalents is $1.21 B
What is United Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, UTHR annual cash & cash equivalents has changed by +$246.50 M (+25.65%)
What is United Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of UTHR is $1.55 B
What is the all time high quarterly cash and cash equivalents for United Therapeutics?
United Therapeutics all-time high quarterly cash and cash equivalents is $1.55 B
What is United Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, UTHR quarterly cash and cash equivalents has changed by +$446.20 M (+40.28%)